An Open-Label Study to Investigate the Efficacy and Safety of Peginesatide in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2016
At a glance
- Drugs Peginesatide (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Takeda
- 29 Oct 2016 This trial has been completed in Germany (End date: 2016-10-24), according to European Clinical Trials Database.
- 27 Oct 2016 Status changed from active, no longer recruiting to completed.
- 21 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov.